ID   PAFA_HUMAN              Reviewed;         441 AA.
AC   Q13093; A5HTT5; Q15692; Q5VTT1; Q8IVA2;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1997, sequence version 1.
DT   10-MAY-2017, entry version 166.
DE   RecName: Full=Platelet-activating factor acetylhydrolase;
DE            Short=PAF acetylhydrolase;
DE            EC=3.1.1.47;
DE   AltName: Full=1-alkyl-2-acetylglycerophosphocholine esterase;
DE   AltName: Full=2-acetyl-1-alkylglycerophosphocholine esterase;
DE   AltName: Full=Group-VIIA phospholipase A2;
DE            Short=gVIIA-PLA2;
DE   AltName: Full=LDL-associated phospholipase A2;
DE            Short=LDL-PLA(2);
DE   AltName: Full=PAF 2-acylhydrolase;
DE   Flags: Precursor;
GN   Name=PLA2G7; Synonyms=PAFAH;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 42-57.
RC   TISSUE=Myeloid;
RX   PubMed=7700381; DOI=10.1038/374549a0;
RA   Tjoelker L.W., Wilder C., Eberhardt C., Stafforini D.M., Dietsch G.,
RA   Schimpf B., Hooper S., le Trong H., Cousens L.S., Zimmerman G.A.,
RA   Yamada Y., McIntyre T.M., Prescott S.M., Gray P.W.;
RT   "Anti-inflammatory properties of a platelet-activating factor
RT   acetylhydrolase.";
RL   Nature 374:549-553(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND PARTIAL PROTEIN SEQUENCE.
RC   TISSUE=Lymphoma;
RX   PubMed=8624782; DOI=10.1161/01.ATV.16.4.591;
RA   Tew D.G., Southan C., Rice S.Q.J., Lawrence M.P., Li H., Boyd H.F.,
RA   Moores K., Gloger I.S., Macphee C.H.;
RT   "Purification, properties, sequencing, and cloning of a lipoprotein-
RT   associated, serine-dependent phospholipase involved in the oxidative
RT   modification of low-density lipoproteins.";
RL   Arterioscler. Thromb. Vasc. Biol. 16:591-599(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS PRO-45; HIS-92;
RP   ASN-191; THR-198 AND ALA-379.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (APR-2007) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ALA-379.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ALA-379.
RC   TISSUE=Blood;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   MUTAGENESIS.
RX   PubMed=7592717; DOI=10.1074/jbc.270.43.25481;
RA   Tjoelker L.W., Eberhardt C., Unger J., le Trong H., Zimmerman G.A.,
RA   McIntyre T.M., Stafforini D.M., Prescott S.M., Gray P.W.;
RT   "Plasma platelet-activating factor acetylhydrolase is a secreted
RT   phospholipase A2 with a catalytic triad.";
RL   J. Biol. Chem. 270:25481-25487(1995).
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 47-429 ALONE AND IN COMPLEX
RP   WITH PARAOXON, AND ACTIVE SITE.
RX   PubMed=18784071; DOI=10.1074/jbc.M804750200;
RA   Samanta U., Bahnson B.J.;
RT   "Crystal structure of human plasma platelet-activating factor
RT   acetylhydrolase: structural implication to lipoprotein binding and
RT   catalysis.";
RL   J. Biol. Chem. 283:31617-31624(2008).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 47-429 IN COMPLEX WITH
RP   ORGANOPHOSPHORUS NERVE AGENTS.
RX   PubMed=19394314; DOI=10.1016/j.bcp.2009.04.018;
RA   Samanta U., Kirby S.D., Srinivasan P., Cerasoli D.M., Bahnson B.J.;
RT   "Crystal structures of human group-VIIA phospholipase A2 inhibited by
RT   organophosphorus nerve agents exhibit non-aged complexes.";
RL   Biochem. Pharmacol. 78:420-429(2009).
RN   [10]
RP   VARIANT PAFAD PHE-279.
RX   PubMed=8675689; DOI=10.1172/JCI118733;
RA   Stafforini D.M., Satoh K., Atkinson D.L., Tjoelker L.W., Eberhardt C.,
RA   Yoshida H., Imaizumi T., Takamatsu S., Zimmerman G.A., McIntyre T.M.,
RA   Gray P.W., Prescott S.M.;
RT   "Platelet-activating factor acetylhydrolase deficiency. A missense
RT   mutation near the active site of an anti-inflammatory phospholipase.";
RL   J. Clin. Invest. 97:2784-2791(1996).
RN   [11]
RP   VARIANT PAFAD ARG-281.
RX   PubMed=9245731; DOI=10.1006/bbrc.1997.7047;
RA   Yamada Y., Yokota M.;
RT   "Loss of activity of plasma platelet-activating factor acetylhydrolase
RT   due to a novel Gln281-->Arg mutation.";
RL   Biochem. Biophys. Res. Commun. 236:772-775(1997).
RN   [12]
RP   VARIANT PAFAD PHE-279.
RX   PubMed=9412624; DOI=10.1161/01.STR.28.12.2417;
RA   Hiramoto M., Yoshida H., Imaizumi T., Yoshimizu N., Satoh K.;
RT   "A mutation in plasma platelet-activating factor acetylhydrolase
RT   (Val279-->Phe) is a genetic risk factor for stroke.";
RL   Stroke 28:2417-2420(1997).
RN   [13]
RP   VARIANT PAFAD PHE-279.
RX   PubMed=9472966; DOI=10.1016/S0026-0495(98)90216-5;
RA   Yamada Y., Ichihara S., Fujimura T., Yokota M.;
RT   "Identification of the G994--> T missense in exon 9 of the plasma
RT   platelet-activating factor acetylhydrolase gene as an independent risk
RT   factor for coronary artery disease in Japanese men.";
RL   Metabolism 47:177-181(1998).
RN   [14]
RP   VARIANT PAFAD PHE-279.
RX   PubMed=9759612;
RA   Yoshida H., Imaizumi T., Fujimoto K., Itaya H., Hiramoto M.,
RA   Yoshimizu N., Fukushi K., Satoh K.;
RT   "A mutation in plasma platelet-activating factor acetylhydrolase
RT   (Val279Phe) is a genetic risk factor for cerebral hemorrhage but not
RT   for hypertension.";
RL   Thromb. Haemost. 80:372-375(1998).
RN   [15]
RP   VARIANTS HIS-92; THR-198 AND ALA-379, AND INVOLVEMENT IN ASTHMA AND
RP   ATOPY.
RX   PubMed=10733466; DOI=10.1086/302901;
RA   Kruse S., Mao X.-Q., Heinzmann A., Blattmann S., Roberts M.H.,
RA   Braun S., Gao P.-S., Forster J., Kuehr J., Hopkin J.M., Shirakawa T.,
RA   Deichmann K.A.;
RT   "The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase
RT   impair catalytical activities and are associated with atopy and
RT   asthma.";
RL   Am. J. Hum. Genet. 66:1522-1530(2000).
CC   -!- FUNCTION: Modulates the action of platelet-activating factor (PAF)
CC       by hydrolyzing the sn-2 ester bond to yield the biologically
CC       inactive lyso-PAF. Has a specificity for substrates with a short
CC       residue at the sn-2 position. It is inactive against long-chain
CC       phospholipids.
CC   -!- CATALYTIC ACTIVITY: 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine +
CC       H(2)O = 1-alkyl-sn-glycero-3-phosphocholine + acetate.
CC   -!- SUBCELLULAR LOCATION: Secreted, extracellular space.
CC   -!- TISSUE SPECIFICITY: Plasma.
CC   -!- DISEASE: Platelet-activating factor acetylhydrolase deficiency
CC       (PAFAD) [MIM:614278]: An enzymatic deficiency that results in
CC       exacerbated bodily response to inflammatory agents. It can be
CC       associated with several disease states including inflammatory
CC       gastrointestinal disorders, asthma and atopy. Asthmatic
CC       individuals with PAFAD may manifest aggravated respiratory
CC       symptoms. {ECO:0000269|PubMed:8675689, ECO:0000269|PubMed:9245731,
CC       ECO:0000269|PubMed:9412624, ECO:0000269|PubMed:9472966,
CC       ECO:0000269|PubMed:9759612}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Asthma (ASTHMA) [MIM:600807]: The most common chronic
CC       disease affecting children and young adults. It is a complex
CC       genetic disorder with a heterogeneous phenotype, largely
CC       attributed to the interactions among many genes and between these
CC       genes and the environment. It is characterized by recurrent
CC       attacks of paroxysmal dyspnea, with wheezing due to spasmodic
CC       contraction of the bronchi. {ECO:0000269|PubMed:10733466}.
CC       Note=Disease susceptibility is associated with variations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Atopic hypersensitivity (ATOPY) [MIM:147050]: A condition
CC       characterized by predisposition to develop hypersensitivity
CC       reactions. Atopic individuals can develop eczema, allergic
CC       rhinitis and allergic asthma. {ECO:0000269|PubMed:10733466}.
CC       Note=Disease susceptibility is associated with variations
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the AB hydrolase superfamily. Lipase
CC       family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/pla2g7/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U20157; AAC50126.1; -; mRNA.
DR   EMBL; U24577; AAB04170.1; -; mRNA.
DR   EMBL; EF568110; ABQ01234.1; -; Genomic_DNA.
DR   EMBL; AL591242; CAH73907.1; -; Genomic_DNA.
DR   EMBL; CH471081; EAX04301.1; -; Genomic_DNA.
DR   EMBL; BC038452; AAH38452.1; -; mRNA.
DR   CCDS; CCDS4917.1; -.
DR   PIR; S60247; S60247.
DR   RefSeq; NP_001161829.1; NM_001168357.1.
DR   RefSeq; NP_005075.3; NM_005084.3.
DR   RefSeq; XP_005249465.1; XM_005249408.4.
DR   UniGene; Hs.584823; -.
DR   PDB; 3D59; X-ray; 1.50 A; A/B=47-429.
DR   PDB; 3D5E; X-ray; 2.10 A; A/B=47-429.
DR   PDB; 3F96; X-ray; 2.10 A; A/B=47-429.
DR   PDB; 3F97; X-ray; 1.70 A; A/B=47-429.
DR   PDB; 3F98; X-ray; 1.70 A; A/B/C=47-429.
DR   PDB; 3F9C; X-ray; 2.30 A; A/B=47-429.
DR   PDB; 5I8P; X-ray; 2.37 A; A/B=47-429.
DR   PDB; 5I9I; X-ray; 2.70 A; A/B=47-429.
DR   PDB; 5JAD; X-ray; 2.05 A; A=46-428.
DR   PDB; 5JAH; X-ray; 2.06 A; A=46-428.
DR   PDB; 5JAL; X-ray; 2.06 A; A=46-428.
DR   PDB; 5JAN; X-ray; 2.12 A; A=46-428.
DR   PDB; 5JAO; X-ray; 2.06 A; A=46-428.
DR   PDB; 5JAP; X-ray; 2.46 A; A=46-428.
DR   PDB; 5JAR; X-ray; 2.11 A; A=46-428.
DR   PDB; 5JAS; X-ray; 2.06 A; A=46-428.
DR   PDB; 5JAT; X-ray; 2.04 A; A=46-428.
DR   PDB; 5JAU; X-ray; 1.95 A; A=46-428.
DR   PDB; 5LP1; X-ray; 1.91 A; A=46-428.
DR   PDB; 5LYY; X-ray; 2.17 A; A=46-428.
DR   PDB; 5LZ2; X-ray; 2.10 A; A=46-428.
DR   PDB; 5LZ4; X-ray; 2.07 A; A=46-428.
DR   PDB; 5LZ5; X-ray; 2.05 A; A=46-428.
DR   PDB; 5LZ7; X-ray; 2.10 A; A=46-428.
DR   PDB; 5LZ8; X-ray; 2.11 A; A=46-428.
DR   PDB; 5LZ9; X-ray; 2.06 A; A=46-428.
DR   PDBsum; 3D59; -.
DR   PDBsum; 3D5E; -.
DR   PDBsum; 3F96; -.
DR   PDBsum; 3F97; -.
DR   PDBsum; 3F98; -.
DR   PDBsum; 3F9C; -.
DR   PDBsum; 5I8P; -.
DR   PDBsum; 5I9I; -.
DR   PDBsum; 5JAD; -.
DR   PDBsum; 5JAH; -.
DR   PDBsum; 5JAL; -.
DR   PDBsum; 5JAN; -.
DR   PDBsum; 5JAO; -.
DR   PDBsum; 5JAP; -.
DR   PDBsum; 5JAR; -.
DR   PDBsum; 5JAS; -.
DR   PDBsum; 5JAT; -.
DR   PDBsum; 5JAU; -.
DR   PDBsum; 5LP1; -.
DR   PDBsum; 5LYY; -.
DR   PDBsum; 5LZ2; -.
DR   PDBsum; 5LZ4; -.
DR   PDBsum; 5LZ5; -.
DR   PDBsum; 5LZ7; -.
DR   PDBsum; 5LZ8; -.
DR   PDBsum; 5LZ9; -.
DR   ProteinModelPortal; Q13093; -.
DR   SMR; Q13093; -.
DR   BioGrid; 113667; 1.
DR   IntAct; Q13093; 3.
DR   STRING; 9606.ENSP00000274793; -.
DR   BindingDB; Q13093; -.
DR   ChEMBL; CHEMBL3514; -.
DR   DrugBank; DB05256; 659032.
DR   GuidetoPHARMACOLOGY; 1432; -.
DR   SwissLipids; SLP:000000204; -.
DR   ESTHER; human-PLA2G7; PAF-Acetylhydrolase.
DR   iPTMnet; Q13093; -.
DR   PhosphoSitePlus; Q13093; -.
DR   BioMuta; PLA2G7; -.
DR   DMDM; 2497687; -.
DR   EPD; Q13093; -.
DR   MaxQB; Q13093; -.
DR   PaxDb; Q13093; -.
DR   PeptideAtlas; Q13093; -.
DR   PRIDE; Q13093; -.
DR   DNASU; 7941; -.
DR   Ensembl; ENST00000274793; ENSP00000274793; ENSG00000146070.
DR   Ensembl; ENST00000537365; ENSP00000445666; ENSG00000146070.
DR   GeneID; 7941; -.
DR   KEGG; hsa:7941; -.
DR   UCSC; uc010jzf.4; human.
DR   CTD; 7941; -.
DR   DisGeNET; 7941; -.
DR   GeneCards; PLA2G7; -.
DR   HGNC; HGNC:9040; PLA2G7.
DR   HPA; HPA035916; -.
DR   MalaCards; PLA2G7; -.
DR   MIM; 147050; phenotype.
DR   MIM; 600807; phenotype.
DR   MIM; 601690; gene.
DR   MIM; 614278; phenotype.
DR   neXtProt; NX_Q13093; -.
DR   OpenTargets; ENSG00000146070; -.
DR   PharmGKB; PA33368; -.
DR   eggNOG; KOG3847; Eukaryota.
DR   eggNOG; ENOG4111FH0; LUCA.
DR   GeneTree; ENSGT00390000005233; -.
DR   HOGENOM; HOG000008053; -.
DR   HOVERGEN; HBG001322; -.
DR   InParanoid; Q13093; -.
DR   KO; K01062; -.
DR   OMA; WLMGNIL; -.
DR   OrthoDB; EOG091G08C2; -.
DR   PhylomeDB; Q13093; -.
DR   TreeFam; TF313831; -.
DR   BRENDA; 3.1.1.4; 2681.
DR   BRENDA; 3.1.1.47; 2681.
DR   Reactome; R-HSA-422085; Synthesis, secretion, and deacylation of Ghrelin.
DR   SABIO-RK; Q13093; -.
DR   EvolutionaryTrace; Q13093; -.
DR   GeneWiki; Lipoprotein-associated_phospholipase_A2; -.
DR   GenomeRNAi; 7941; -.
DR   PRO; PR:Q13093; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   Bgee; ENSG00000146070; -.
DR   CleanEx; HS_PLA2G7; -.
DR   Genevisible; Q13093; HS.
DR   GO; GO:0005737; C:cytoplasm; IEA:Ensembl.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0034362; C:low-density lipoprotein particle; IDA:BHF-UCL.
DR   GO; GO:0003847; F:1-alkyl-2-acetylglycerophosphocholine esterase activity; IDA:BHF-UCL.
DR   GO; GO:0047499; F:calcium-independent phospholipase A2 activity; IDA:BHF-UCL.
DR   GO; GO:0016788; F:hydrolase activity, acting on ester bonds; TAS:Reactome.
DR   GO; GO:0005543; F:phospholipid binding; IDA:BHF-UCL.
DR   GO; GO:0016042; P:lipid catabolic process; IEA:UniProtKB-KW.
DR   GO; GO:0034440; P:lipid oxidation; IDA:BHF-UCL.
DR   GO; GO:0034374; P:low-density lipoprotein particle remodeling; IDA:BHF-UCL.
DR   GO; GO:0034441; P:plasma lipoprotein oxidation; IDA:BHF-UCL.
DR   GO; GO:0046469; P:platelet activating factor metabolic process; IDA:BHF-UCL.
DR   GO; GO:0050729; P:positive regulation of inflammatory response; TAS:BHF-UCL.
DR   GO; GO:0090026; P:positive regulation of monocyte chemotaxis; IDA:BHF-UCL.
DR   Gene3D; 3.40.50.1820; -; 1.
DR   InterPro; IPR029058; AB_hydrolase.
DR   InterPro; IPR005065; PAF_acetylhydro-like.
DR   InterPro; IPR016715; PAF_acetylhydro_eukaryote.
DR   PANTHER; PTHR10272; PTHR10272; 1.
DR   Pfam; PF03403; PAF-AH_p_II; 1.
DR   PIRSF; PIRSF018169; PAF_acetylhydrolase; 1.
DR   SUPFAM; SSF53474; SSF53474; 3.
DR   PROSITE; PS00120; LIPASE_SER; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Asthma; Complete proteome; Direct protein sequencing;
KW   Disease mutation; Glycoprotein; Hydrolase; Lipid degradation;
KW   Lipid metabolism; Polymorphism; Reference proteome; Secreted; Signal.
FT   SIGNAL        1     21
FT   CHAIN        22    441       Platelet-activating factor
FT                                acetylhydrolase.
FT                                /FTId=PRO_0000017833.
FT   ACT_SITE    273    273       Nucleophile.
FT                                {ECO:0000269|PubMed:18784071}.
FT   ACT_SITE    296    296       Charge relay system.
FT                                {ECO:0000255|PROSITE-ProRule:PRU10037,
FT                                ECO:0000269|PubMed:18784071}.
FT   ACT_SITE    351    351       Charge relay system.
FT                                {ECO:0000255|PROSITE-ProRule:PRU10037,
FT                                ECO:0000269|PubMed:18784071}.
FT   CARBOHYD    423    423       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    433    433       N-linked (GlcNAc...) asparagine.
FT   VARIANT      45     45       L -> P (in dbSNP:rs45521937).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_047970.
FT   VARIANT      92     92       R -> H (common polymorphism;
FT                                dbSNP:rs1805017).
FT                                {ECO:0000269|PubMed:10733466,
FT                                ECO:0000269|Ref.3}.
FT                                /FTId=VAR_011583.
FT   VARIANT     191    191       K -> N (in dbSNP:rs45454695).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_047971.
FT   VARIANT     198    198       I -> T (common polymorphism; associated
FT                                with asthma and atopy; dbSNP:rs1805018).
FT                                {ECO:0000269|PubMed:10733466,
FT                                ECO:0000269|Ref.3}.
FT                                /FTId=VAR_011584.
FT   VARIANT     279    279       V -> F (in PAFAD; loss of function; risk
FT                                factor for coronary arthery disease and
FT                                stroke; dbSNP:rs76863441).
FT                                {ECO:0000269|PubMed:8675689,
FT                                ECO:0000269|PubMed:9412624,
FT                                ECO:0000269|PubMed:9472966,
FT                                ECO:0000269|PubMed:9759612}.
FT                                /FTId=VAR_004268.
FT   VARIANT     281    281       Q -> R (in PAFAD; loss of function;
FT                                dbSNP:rs201256712).
FT                                {ECO:0000269|PubMed:9245731}.
FT                                /FTId=VAR_011585.
FT   VARIANT     379    379       V -> A (common polymorphism;
FT                                dbSNP:rs1051931).
FT                                {ECO:0000269|PubMed:10733466,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|Ref.3, ECO:0000269|Ref.5}.
FT                                /FTId=VAR_011586.
FT   MUTAGEN     108    108       S->A: Activity is higher than wild-type.
FT                                {ECO:0000269|PubMed:7592717}.
FT   MUTAGEN     273    273       S->A: Loss of activity.
FT                                {ECO:0000269|PubMed:7592717}.
FT   MUTAGEN     286    286       D->A: Almost no activity.
FT                                {ECO:0000269|PubMed:7592717}.
FT   MUTAGEN     286    286       D->N: Diminishes activity.
FT                                {ECO:0000269|PubMed:7592717}.
FT   MUTAGEN     296    296       D->A: Loss of activity.
FT                                {ECO:0000269|PubMed:7592717}.
FT   MUTAGEN     296    296       D->N: Loss of activity.
FT                                {ECO:0000269|PubMed:7592717}.
FT   MUTAGEN     304    304       D->A: No change in activity.
FT                                {ECO:0000269|PubMed:7592717}.
FT   MUTAGEN     338    338       D->A: Activity is higher than wild-type.
FT                                {ECO:0000269|PubMed:7592717}.
FT   MUTAGEN     351    351       H->A: Loss of activity.
FT                                {ECO:0000269|PubMed:7592717}.
FT   STRAND       54     56       {ECO:0000244|PDB:3F98}.
FT   STRAND       61     75       {ECO:0000244|PDB:3D59}.
FT   STRAND       78     88       {ECO:0000244|PDB:3D59}.
FT   STRAND       95     98       {ECO:0000244|PDB:3D59}.
FT   HELIX       101    111       {ECO:0000244|PDB:3D59}.
FT   HELIX       115    125       {ECO:0000244|PDB:3D59}.
FT   STRAND      129    134       {ECO:0000244|PDB:3D59}.
FT   STRAND      144    150       {ECO:0000244|PDB:3D59}.
FT   TURN        157    160       {ECO:0000244|PDB:3D59}.
FT   HELIX       161    169       {ECO:0000244|PDB:3D59}.
FT   STRAND      173    177       {ECO:0000244|PDB:3D59}.
FT   STRAND      184    189       {ECO:0000244|PDB:3D59}.
FT   HELIX       193    198       {ECO:0000244|PDB:3D59}.
FT   STRAND      202    205       {ECO:0000244|PDB:3D59}.
FT   HELIX       211    213       {ECO:0000244|PDB:3D59}.
FT   HELIX       214    240       {ECO:0000244|PDB:3D59}.
FT   HELIX       255    258       {ECO:0000244|PDB:3D59}.
FT   STRAND      262    272       {ECO:0000244|PDB:3D59}.
FT   HELIX       274    285       {ECO:0000244|PDB:3D59}.
FT   STRAND      291    296       {ECO:0000244|PDB:3D59}.
FT   HELIX       304    308       {ECO:0000244|PDB:3D59}.
FT   STRAND      314    319       {ECO:0000244|PDB:3D59}.
FT   TURN        320    322       {ECO:0000244|PDB:3D59}.
FT   HELIX       325    332       {ECO:0000244|PDB:3D59}.
FT   STRAND      337    339       {ECO:0000244|PDB:3F96}.
FT   STRAND      341    346       {ECO:0000244|PDB:3D59}.
FT   HELIX       351    354       {ECO:0000244|PDB:3D59}.
FT   HELIX       356    359       {ECO:0000244|PDB:3D59}.
FT   HELIX       363    368       {ECO:0000244|PDB:3D59}.
FT   HELIX       377    396       {ECO:0000244|PDB:3D59}.
FT   HELIX       402    405       {ECO:0000244|PDB:3D59}.
FT   HELIX       406    409       {ECO:0000244|PDB:3D59}.
FT   STRAND      416    419       {ECO:0000244|PDB:3D59}.
SQ   SEQUENCE   441 AA;  50077 MW;  3BA9EEA9E8094A57 CRC64;
     MVPPKLHVLF CLCGCLAVVY PFDWQYINPV AHMKSSAWVN KIQVLMAAAS FGQTKIPRGN
     GPYSVGCTDL MFDHTNKGTF LRLYYPSQDN DRLDTLWIPN KEYFWGLSKF LGTHWLMGNI
     LRLLFGSMTT PANWNSPLRP GEKYPLVVFS HGLGAFRTLY SAIGIDLASH GFIVAAVEHR
     DRSASATYYF KDQSAAEIGD KSWLYLRTLK QEEETHIRNE QVRQRAKECS QALSLILDID
     HGKPVKNALD LKFDMEQLKD SIDREKIAVI GHSFGGATVI QTLSEDQRFR CGIALDAWMF
     PLGDEVYSRI PQPLFFINSE YFQYPANIIK MKKCYSPDKE RKMITIRGSV HQNFADFTFA
     TGKIIGHMLK LKGDIDSNVA IDLSNKASLA FLQKHLGLHK DFDQWDCLIE GDDENLIPGT
     NINTTNQHIM LQNSSGIEKY N
//
